Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Here's Why Sage Therapeutics Tanked This Week
07:00am, Saturday, 19'th Jun 2021
The neuroscience-focused biotech company didn't give investors the result they wanted.
4 Undervalued Biotech Stocks That Belong On Every Investor's Buy List
04:36pm, Thursday, 17'th Jun 2021
Searching for undervalued biotech stocks? Here are 4 biotech stocks to buy for a mix of value and growth in any portfolio.
Sage Stock Declines on Late-Stage Depression Study Data
11:17am, Wednesday, 16'th Jun 2021
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
Here's Why Sage Therapeutics Stock Is Sliding Today
01:21pm, Tuesday, 15'th Jun 2021
Long-awaited clinical trial results weren't as successful as hoped.
Here's why Sage Therapeutics fell 18% on Tuesday morning
12:51pm, Tuesday, 15'th Jun 2021
Sage Therapeutics Inc (NASDAQ: SAGE) said on Tuesday its candidate drug for depression that it developed in collaboration with Biogen Inc was found effective in alleviating the symptoms, as per the re
SAGE Plummets After Drug Trial Results
11:07am, Tuesday, 15'th Jun 2021
The shares of Sage Therapeutics Inc (NASDAQ:SAGE) are down 16.5% to trade at $60.85 at last check, following lackluster Phase 3 test results for the biotechnology company's depression drug, Zuranolone
SAGE Stock Price Falls Over 10% Pre-Market: Why It Happened
08:55am, Tuesday, 15'th Jun 2021
The stock price of SAGE Therapeutics Inc (NASDAQ: SAGE) fell by over 10% pre-market. This is why it happened.
Sage Therapeutics to Host Conference Call
07:47am, Tuesday, 15'th Jun 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debili
Sage Therapeutics - Biogen's Zuranolone Tops Placebo In Reducing Depressive Symptoms
07:16am, Tuesday, 15'th Jun 2021
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced data from WATERFALL Phase 3 study evaluating zuranolone (SAGE-217/BIIB125) in patients with Major Depressive Dis
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
10:27am, Wednesday, 02'nd Jun 2021
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
These Canadian Cannabis Producers May Benefit From an Israeli Medical Innovation
06:17am, Monday, 31'st May 2021
A first-of-its-kind medical device from a top-10 biotech could change medical cannabis consumption.
Is the Options Market Predicting a Spike in Sage Therapeutics (SAGE) Stock?
09:46am, Thursday, 27'th May 2021
Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilit
Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options
09:55am, Thursday, 13'th May 2021
Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.
Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth
06:30am, Thursday, 13'th May 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debili
